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Cancer-testis gene expression is associated with
the methylenetetrahydrofolate reductase 677 C>T
polymorphism in non-small cell lung carcinoma
Kerem M Senses1, Mithat Gonen2, Ahmet R Barutcu1,6, Zeynep Kalaylioglu3, Murat Isbilen1, Ozlen Konu1,
Yao T Chen4, Nasser K Altorki5 and Ali O Gure1*
Abstract
Background: Tumor-specific, coordinate expression of cancer-testis (CT) genes, mapping to the X chromosome, is
observed in more than 60% of non-small cell lung cancer (NSCLC) patients. Although CT gene expression has been
unequivocally related to DNA demethylation of promoter regions, the underlying mechanism leading to loss of
promoter methylation remains elusive. Polymorphisms of enzymes within the 1-carbon pathway have been shown
to affect S-adenosyl methionine (SAM) production, which is the sole methyl donor in the cell. Allelic variants of
several enzymes within this pathway have been associated with altered SAM levels either directly, or indirectly as
reflected by altered levels of SAH and Homocysteine levels, and altered levels of DNA methylation. We, therefore,
asked whether the five most commonly occurring polymorphisms in four of the enzymes in the 1-carbon pathway
associated with CT gene expression status in patients with NSCLC.
Methods: Fifty patients among a cohort of 763 with NSCLC were selected based on CT gene expression status and
typed for five polymorphisms in four genes known to affect SAM generation by allele specific q-PCR and RFLP.
Results: We identified a significant association between CT gene expression and the MTHFR 677 CC genotype, as
well as the C allele of the SNP, in this cohort of patients. Multivariate analysis revealed that the genotype and allele
strongly associate with CT gene expression, independent of potential confounders.
Conclusions: Although CT gene expression is associated with DNA demethylation, in NSCLC, our data suggests this
is unlikely to be the result of decreased MTHFR function.
Keywords: Cancer-testis genes, 1-carbon pathway, Adomet, DNA methylation
Background
Cancer-testis (CT), or cancer-germline genes, currently
with more than 100 members, are distinctly expressed in
cancer, germline and trophoblast cells but not in other
normal tissues in the adult. Most CT genes constitute
multigene families organized in clusters along the X
chromosome. Members within a family are highly hom-
ologous, however, no conservation of sequence exists be-
tween families [1]. Despite the lack of sequence similarity
(including promoters), re-expression of almost all CT
genes in tumors correlates with the demethylation of their
promoters that occurs in parallel to a genome-wide de-
methylation event, primarily affecting repeat regions [2].
The mechanisms leading to CT gene promoter demethyla-
tion in cancer are unknown. Increased BORIS expression
has been associated with upregulated CT gene expression
[3,4], but the protein is likely not the sole responsible fac-
tor in this event. Histone acetylation has also been shown
to facilitate CT gene expression, primarily when it associ-
ates with DNA demethylation [5].
As most CT gene products are highly antigenic they
have been utilized in clinical trials based on immunothera-
peutic approaches targeting these antigens [6]. Since pa-
tient eligibility for CT targeting immunotherapy requires
that the tumor express CT genes, it is important to know
whether CT gene expression can be induced. It is expected
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that any approach leading to CT gene expression should
also result in the demethylation of their promoters.
Production of the sole methyl donor in the cell,
S-adenosylmethionine (SAM), depends on the efficient
utilization of folate, by the 1-carbon pathway. Several
enzymes in this pathway contain common polymorphic
variants that reduce the efficiency of the enzyme and
thus, the rate of SAM production. Hypomorphic alleles
of four of these enzymes (methylenetetrahydrofolate
reductase (MTHFR), methionine synthase reductase
(MTRR), methionine synthase (MTR), and reduced fol-
ate carrier (RFC)), have been associated with cellular
under-utilization of folate and homocysteine, increased
DNA hypomethylation, and decreased CpG methylation
[7-11]. More recently, the hypomorphic 677 T allele of
MTHFR, has been associataed with the expression of
MAGE-A1, a CT gene, in glioblastoma multiforme [12].
Others, however, could not reproduce these findings in
ovarian carcinoma [13]. In the present study we asked if
polymorphisms of the 1-carbon pathway enzymes asso-
ciate with CT gene expression in non-small cell lung
cancer (NSCLC) patients. Our results show a strong as-
sociation between the MTHFR677 CC genotype as well
as the MTHFR 677 C allele and CT gene expression in-
dependent of age, sex, histology, and tumor stage.
Methods
Patients and tumor material
Tumor samples obtained from patients undergoing cura-
tive surgical resection for primary NSCLC at the Depart-
ment of Cardio-Thoracic Surgery, Weill Medical College of
Cornell University, from 1991 to July 2005 were analyzed
in this study. Informed consent was obtained from all pa-
tients. The study was approved by the Institutional Review
Board of Weill Medical College of Cornell University. Fifty
tumor samples were selected solely based on CT gene ex-
pression from 763 samples that had been evaluated for the
presence of transcripts from up to 9 CT genes (NY-ESO-1,
LAGE-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10,
CT-7, SSX2, and SSX4), by semi-quantitative PCR, as de-
scribed previously [14]. Twenty one samples with CT ex-
pression in at least 4 of the 9 CT genes tested, with strong
expression in at least one gene, constituted the CT (+)
group. Twenty-nine samples with no CT expression in any
of the CT genes tested (with a minimum of 5 CT genes
tested) were selected as CT (-) tumors for this study. CT
gene expression was determined as strong (+++), inter-
mediate (++), weak (+ or +/-), or none (-) as previously
described [14], and is shown in Additional file 1: Table S1.
DNA analysis
Genomic DNA extracted from tumor tissues were geno-
typed using pre-designed 5’-nuclease TaqMan SNP geno-
typing assays (Applied Biosystems, Foster City, CA) using
a Stratagene Mx3005P instrument according to the manu-
facturer’s instructions. The SNPs typed and their reference
IDs were: MTHFR 677 C> T (rs1801133), MTHFR 1298
A>C (rs1801131), MTR 2756 A>G (rs1805087), and
MTRR 66 A>G (rs1801394). Nested PCR-RFLP was used
to type the RFC 80 G>A (rs1051266) polymorphism for
which the first round PCR conditions were previously de-
scribed [10]. Nested PCR primers were: 5’- AGCCGTAGA
AGCAAAGGTAGC-3’ and 5’-AGCGTCACCTTCGTCC
CCTC-3’. PCR was performed using DyNAzyme™ II Hot
Start DNA Polymerase (Finnzymes, Keilaranta, Finland).
PCR conditions were: 10’ activation at 94°C, followed by
35 cycles of 94°C, 62°C and 72°C; 30” each, with a final
72°C, 7’ extension. HinP1I (New England Biolabs, Hert-
fordshire, UK) digested PCR products were analyzed as
described previously [10]. All analyses were repeated at
least twice.
Genotypes for all polymorphisms were determined
successfully in all cases (Additional file 2: Table S2).
Genotype distributions did not deviate from Hardy-
Weinberg equilibrium (Additional file 3: Table S3).
Minor allele frequencies for individual loci were: 40%
for MTHFR 677 C > T, 26% for MTHFR 1298 A > C,
14% for MTR 2756 A > G, 54% for MTRR 66, and 42%
for RFC 80 G > A. MTHFR genotypes were not inde-
pendently distributed across the 2 loci. The major 677C
allele was in linkage disequilibrium with the minor
1298C allele (D’ = 0.99, r2 = 0.23) [15].
In silico association analysis
Paired datasets, GSE14471 and GSE15714, containing
gene expression and SNP genotyping data, respectively,
from 111 pediatric acute myeloid leukemia samples (of
which 109 were typed successfully), were analyzed for
an association between CT gene expression and MTHFR
677 genotype distribution [16]. A principal component
analysis using 44 probesets corresponding to 9 CT gene
families was performed for the expression dataset. The
first principal component, explaining 0.48 of variance
for CT gene expression was used to generate groups
representing samples with low, intermediate, and high
CT gene expression by K means clustering using a cus-
tomized R code [17]. Optimum number of clusters
according to Elbow criterion was determined as five.
Therefore, five initial cluster centers were placed
equally distant from each other where the first and last
centers represented the minimum and maximum values
of PC1, respectively. Centers were iteratively updated
based on the median value of the reassigned cluster
members until no change in cluster membership took
place. The five clusters were regrouped into three
representing low (clusters 1 & 2), intermediate (cluster
3), and high CT gene expression (clusters 4 & 5).
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Statistical analysis
To analyze the association between 1-carbon pathway en-
zyme polymorphisms and CTgene expression, the genotype
distributions were compared in CT (+) and CT (-) tumors
by Pearson’s Chi-Square (2 degrees of freedom) or Fisher’s
exact tests. Odds ratios (OR) were estimated by multivariate
logistic regression. To evaluate whether CT gene expression
was related to sex, smoking status, tumor size, and disease
stage, Fisher's exact test or Chi-square tests were used. Race
information was available for only 29 patients of which 25
were non-Hispanic white, one was a non-Hispanic black,
and 3 were of mixed race, and was not included in statistical
analyses. All statistical tests were two-sided with a 5% type I
error rate, unless indicated otherwise, and were carried out
using SAS (version 9.3) software (SAS Institute, Cary, NC).
P < 0.05 was considered statistically significant.
Results
Demographics and clinical characteristics of patients and
their distribution within CT (+) and (-) groups are shown
in Table 1 and Additional file 1: Table S1. Tumors with
non-squamous cell carcinoma histology and earlier tumor
stage (T stage) showed lower CT gene expression, similar
to what has been reported previously [14]. Distribution of
individual genotypes among CT (+) and (-) tumors are
shown in Table 2 and Additional file 2: Table S2. A signifi-
cant association between the MTHFR 677CC genotype
and CT expression was observed (P = 0.03). CT expres-
sion was not related to any other genotype tested. A multi-
variate logistic regression analysis (MVA) of CT gene
expression that included the MTHFR 677 genotype distri-
bution, age, sex, histology and T stage revealed that the
MTHFR 677 genotype and histology were independent
predictors of CT gene expression in this cohort (Table 3).
The MTHFR 677 SNP was found to be associated with
CT gene expression when analyzed on a per allele basis,
controlling for confounding factors, while other markers
were not (Table 4). We performed an in silico association
analysis for CT expression and the MTHFR 677 genotype
using two datasets derived from childhood acute myeloid
leukemia (AML) where both gene expression and SNP
genotyping data were available [16]. This analysis, how-
ever, did not reveal a statistically significant association be-
tween these two parameters (Table 5 and Additional file 4:
Figure S1).
Table 1 Demographics and clinical characteristics
CT (+)
patients
(n=21)
CT (-)
patients
(n=29)
P*
Age >60 12 19 0.74
<=60 6 7
Unknown$ 3 3
Sex Male 10 12 0.76
Female 8 14
Unknown 3 3
Smoking history No 1 5 0.37
Yes 15 18
Unknown 5 6
Histology SQCC# 8 2 0.002
non-
SQCC
7 24
Unknown 6 3
Pathological tumor size >3 cm 10 8 0.21
<=3 cm 8 17
Unknown 3 4
T stage 1 5 14 0.007
2 8 12
3 3 0
4 2 0
Unknown 3 3
TNM stage (Pathologic
stage of primary tumor)
I 9 18 0.37
II 5 3
III 4 5
IV 0 0
Unknown 3 3
* Chi-square (Fisher's exact test, two sided) or chi-square test for trend; # SQCC
Squamous cell carcinoma; $patients with missing clinical data were not
included in statistical analyses.
Table 2 Distribution of individual genotypes among CT
(+) and CT (-) tumors
Polymorphism Genotype CT (+)
Tumors, n
(%)
CT (-)
Tumors, n
(%)
χ2 P*
MTHFR 677 C>T
(rs1801133)
CC 13 (62%) 7 (24%) 7.30 0.03
CT 5 (24%) 15 (52%)
TT 3 (14%) 7 (24%)
MTHFR 1298 A>C
(rs1801131)
AA 13 (62%) 14 (48%) 0.91 0.63
AC 7 (33%) 13 (45%)
CC 1 (5%) 2 (7%)
MTR 2756 A>G
(rs1805087)
AA 14 (67%) 22 (76%) 0.51 0.53**
AG 7 (33%) 7 (24%)
GG 0 (0%) 0 (0%)
MTRR 66 A>G
(rs1801394)
AA 4 (19%) 9 (31%) 0.92 0.63
AG 10 (48%) 12 (41%)
GG 7 (33%) 8 (28%)
RFC 80 G>A
(rs1051266)
GG 6 (29%) 12 (41%) 1.90 0.39
GA 9 (43%) 13 (45%)
AA 6 (29%) 4 (14%)
* Chi-square (2 degrees of freedom); ** Fisher’s exact test, two sided.
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Discussion
Among the five markers analyzed in this study, we find a
strong association between the major MTHFR 677 CC
genotype, as well as the MTHFR 677 C allele and CT gene
expression in lung cancer. This contrasts with earlier stud-
ies where the minor allele of this SNP was associated with
decreased SAM production, decreased methylation levels
and decreased MAGE-A1 expression [12]. Although our
analysis included only 7% of patients within a large cohort
with the highest and lowest amount of CT gene expression,
we don’t think this is a reason for bias, as the distribution
of the 1-carbon pathway genotypes of our samples are
similar to those where much larger lung cancer patient co-
horts were evaluated [18-20]. Tumors of squamous cell
histology were previously identified as showing more fre-
quent and stronger CT gene expression; however, MVA
shows that the association betweenMTHFR 677 CC geno-
type or the C allele of the same polymorphism and CT
gene expression is independent of histology. On the other
hand, tumor type is known to affect CT gene expression
rates, as some blood-derived tumors and cancers originat-
ing from the kidney rarely express CT genes [21]. In this
line, one reason for our inability to replicate our q-PCR
based results in silico might be related to the fact that
AML is not a tumor with strong CT expression and thus,
the K-means based classification of this tumor is some-
what artificial. Therefore, a similar analysis with datasets
ideally derived from lung cancer might reveal associations
not identified in this study.
We calculated the sample size that would give us 80%
power to detect a significant association between poly-
morphisms other than MTHFR 677 and CT gene expres-
sion using the observed effect sizes in this study as true
values. We found that at least 250 patients would be
required to find one more polymorphism significant.
Therefore, analysis of larger cohorts might reveal add-
itional associations as well as compound effects of SNPs
within the 1-carbon pathway enzymes on CT gene ex-
pression. Models to test for such effects were not com-
puted in this study due to the limited sample size.
Although decreased SAM levels might be expected to
result in DNA demethylation, the exact SAM concentra-
tion threshold required for gene re-expression might be
affected by various other parameters not tested in this
study. A candidate is thymidylate synthase (TS) whose
levels are known to fluctuate widely in cancer and which
can inhibit MTHFR activity [22]. CT gene expression is as-
sociated with larger tumors and advanced stage [14].
If this is to be taken as a sign of increased proliferation, it
would imply increased TS activity, and thus, possibly
suppressed MTHFR, which in turn could affect CT gene
expression. On the other hand, increased SAM production
might indirectly inhibit methylation reactions via methyl-
thioadenosine (MTA), a nucleoside produced from SAM
through the polyamine biosynthetic pathway. MTA can
strongly inhibit H3K4 methylation, possibly by inhibiting
Set1 methyltransferase, which could in turn result in
repressed CT gene expression [23-25]. Future studies are
necessary to explain which of these primarily affect methy-
lation rates and thus CT gene expression in cancer.
Conclusion
Why some NSCLC cells express CT genes when others
don’t, remains an interesting and unanswered question.
We show a strong association between the normoactive
allele of MTHFR 677 and CT gene expression in this
study. This argues against the hypothesis of low level
MTHFR activity leading to DNA hypomethylation, which
in turn could lead to genome-wide hypomethylation and
Table 3 Multivariate analysis of CT gene expression with
MTHFR 677 genotypes
Parameter OR 95% CI P*
MTHFR 677 C>T (rs1801133) CC 32.33 2.42-431.52 0.003
CT/TT 1**
Age$ 1.03 0.94-1.12 0.69
Sex(female vs. male) 0.28‡ 0.02-3.86 0.52
Histology SQCC# 18.46 1.19-284.49 0.04
non-SQCC 1**
T Stage T1 0.31 0.03-3.56 0.53
T2, 3, 4 1**
* Computed from a logistic regression model using the EXACT option of PROC
LOGISTIC in SAS to account for the small data set; $continuous variable.
# SQCC Squamous cell carcinoma; ‡reference = male; **reference group.
Table 4 Multivariate logistic regression modeling of
association between 1-carbon enzyme alleles and CT
gene expression
Polymorphism OR$ 95% CI P*
MTHFR 677 (rs1801133) 13.18 1.96-88.5 0.004
MTHFR 1298 (rs1801131) 0.56 0.15-2.09 0.53
MTR 2756 (rs1805087) 0.81 0.14-4.75 1
MTRR 66 (rs1801394) 0.67 0.22-2.00 0.52
RFC 80 (rs1051266) 0.7 0.24-2.07 0.62
$ Based on number of major alleles, adjusted for age, sex, histology and
t stage; * computed using the EXACT option of PROC LOGISTIC in SAS to
account for the small data set.
Table 5 In silico correlation of CT gene expression with
MTHFR 677 genotypes in acute Myeloid Leukemia
CT gene
expression
clusters
MTHFR 677 C>T (rs1801133) P
(chi-square)CC CT/TT Untyped*
High 15 16 0 0.17
Intermediate 20 13 0
Low 29 16 2
* Untyped samples were not included in analysis.
Senses et al. BMC Medical Genetics 2013, 14:97 Page 4 of 6
http://www.biomedcentral.com/1471-2350/14/97
CT gene expression. However, due to the limited power of
this study, we might have missed individual or cumulative
effects of SNPs within other enzymes of the 1-carbon
pathway on CT gene expression. SAM/SAH ratios for the
tissues analyzed here were also unknown. Hence, we only
contributed to, but did not resolve this interesting story,
and hope future studies reveal the intricacies of the rela-
tion between CT gene expression and genetic variants of
the 1-carbon pathway enzyme genes.
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Additional file 1: Table S1. CT Gene Expression and Distribution of
Clinical Parameters within NSCLC Patients.
Additional file 2: Table S2. Genotypes of NSCLC Patients.
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Additional file 4: Figure S1. Principal component analysis based in
silico clustering of AML. Tumor samples are shown ordered from the
lowest to the highest first principal component (PC1) value. The 5
clusters generated by K-means clustering are indicated. Tumors with low,
intermediate and high CT gene expression correspond to clusters 1-2, 3,
and 4-5, respectively.
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